98 related articles for article (PubMed ID: 15261434)
1. Prognostic factors in malignant mesothelioma.
Burgers JA; Damhuis RA
Lung Cancer; 2004 Aug; 45 Suppl 1():S49-54. PubMed ID: 15261434
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in mesothelioma.
Steele JP; Klabatsa A; Fennell DA; Palläska A; Sheaff MT; Evans MT; Shamash J; Rudd RM
Lung Cancer; 2005 Jul; 49 Suppl 1():S49-52. PubMed ID: 15894403
[TBL] [Abstract][Full Text] [Related]
3. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
[TBL] [Abstract][Full Text] [Related]
4. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in mesothelioma staging.
Richards WG
Semin Thorac Cardiovasc Surg; 2009; 21(2):105-10. PubMed ID: 19822281
[TBL] [Abstract][Full Text] [Related]
6. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
Flores RM; Routledge T; Seshan VE; Dycoco J; Zakowski M; Hirth Y; Rusch VW
J Thorac Cardiovasc Surg; 2008 Sep; 136(3):605-10. PubMed ID: 18805259
[TBL] [Abstract][Full Text] [Related]
7. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
[TBL] [Abstract][Full Text] [Related]
8. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
[TBL] [Abstract][Full Text] [Related]
9. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
10. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Cancer; 2004 Aug; 101(3):587-95. PubMed ID: 15274072
[TBL] [Abstract][Full Text] [Related]
11. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
Francart J; Vaes E; Henrard S; Legrand C; Baas P; Gaafar R; van Meerbeeck JP; Sylvester R; Robert A
Eur J Cancer; 2009 Sep; 45(13):2304-11. PubMed ID: 19502050
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
Pinton G; Brunelli E; Murer B; Puntoni R; Puntoni M; Fennell DA; Gaudino G; Mutti L; Moro L
Cancer Res; 2009 Jun; 69(11):4598-604. PubMed ID: 19487281
[TBL] [Abstract][Full Text] [Related]
14. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
[TBL] [Abstract][Full Text] [Related]
15. Staging and response to therapy of malignant pleural mesothelioma.
Heelan R
Lung Cancer; 2004 Aug; 45 Suppl 1():S59-61. PubMed ID: 15261435
[TBL] [Abstract][Full Text] [Related]
16. Malignant mesothelioma 2008.
Zervos MD; Bizekis C; Pass HI
Curr Opin Pulm Med; 2008 Jul; 14(4):303-9. PubMed ID: 18520263
[TBL] [Abstract][Full Text] [Related]
17. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
Sterman DH; Albelda SM
Respirology; 2005 Jun; 10(3):266-83. PubMed ID: 15955137
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
19. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution.
Nonaka D; Kusamura S; Baratti D; Casali P; Cabras AD; Younan R; Rosai J; Deraco M
Cancer; 2005 Nov; 104(10):2181-8. PubMed ID: 16206294
[TBL] [Abstract][Full Text] [Related]
20. Tnm independent prognostic factors in lung cancer.
Kawamukai K; Cesario A; Margaritora S; Meacci E; Piraino A; Vita ML; Tessitore A; Cusumano G; Granone P
Rays; 2004; 29(4):373-6. PubMed ID: 15852722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
